Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis

December 8, 2010 By Bio-Medicine.Org

SAN DIEGO, Dec. 8, 2010 /PRNewswire/ — Prometheus Laboratories
Inc., a specialty pharmaceutical and diagnostic company, announced
today the execution of an oncology-focused mutational analysis
services agreement with Bayer Schering Pharma AG, Germany, a
worldwide leading pharmaceutical company. The addition of this
mutational analysis services agreement broadens Bayer’s
oncology-focused molecular and pathway activation profiling
collaboration with Prometheus to include comprehensive mutational
analyses.  The expanded information derived from this
agreement has the potential to improve patient stratification in
clinical studies and accelerate the development of novel oncology
diagnostic and therapeutic products.

Under the terms of this agreement, Bayer will provide clinical
samples, sourced from clinical studies, and Prometheus will perform
mutational analyses that characterize the presence or absence of
existing and novel cancer-relevant mutations in these samples.
Prometheus will be compensated based on the number and complexity
of mutational analyses it completes for Bayer.

“This agreement represents further validation of the importance
of our oncology focused CEER and mutational analysis platforms,”
said Joseph M. Limber, President and Chief Executive Officer of
Prometheus. “The combination of our mutational analysis and CEER
platforms that this agreement represents is an important step to
providing a more comprehensive analysis to Bayer, that may result
in improved selection of patients who will benefit the most from
specific drug candidates Bayer is developing. We believe this
collaboration has the potential to ultimately result in improved
outcomes for patients.”

Prometheus and Bayer entered into a research collaboration and
license agreement in March of this year. This collaboration
partners Prometheus’ proprietary oncology diagnostic CEER platform
with Bayer’s broad oncology pipeline with the objective of
stratifying patients to

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech